Cellectis S.A. (LON:0WA2)

Market Cap	82.92M
Revenue (ttm)	39.31M
Net Income (ttm)	-29.36M
Shares Out	n/a
EPS (ttm)	-0.33
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,346
Average Volume	1,649
Open	1.349
Previous Close	1.348
Day's Range	1.338 - 1.344
52-Week Range	1.199 - 2.453
Beta	3.38
RSI	55.76
Earnings Date	May 7, 2025

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acut...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1999
• Employees: 222
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0WA2

Financial Performance

In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.

Financial numbers in USD